ANZUP at ASCO 2025 – ENZA-p

Predictive and prognostic value of baseline PSMA-PET total tumor volume (TTV) and UVmean within a randomised phase 2 trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901)

Oral presentation by Prof Louise Emmett. The results of the ENZA-p trial received global recognition earlier this year when it showed that the combination of the radioligand treatment LuPSMA with enzalutamide helped people with poor-risk metastatic castrate resistant prostate cancer live longer and better lives. Professor Emmett now shows that total tumour volume as measured with PSMA-PET imaging is a reliable prognostic test for overall survival when people are treated with enzalutamide alone and predictive of the combination with LuPSMA. PSMA Standardized Uptake Value (SUV) mean was not prognostic for progression free or overall survival for the combination. The study revealed insights into the use of PSMA PET imaging for predicting response to therapy.